(NMR) Nomura Holdings - Overview
Stock: Investment Consulting, Asset Management, Securities Trading, Underwriting, Advisory
| Risk 5d forecast | |
|---|---|
| Volatility | 33.2% |
| Relative Tail Risk | -9.79% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.31 |
| Alpha | 28.17 |
| Character TTM | |
|---|---|
| Beta | 1.178 |
| Beta Downside | 1.377 |
| Drawdowns 3y | |
|---|---|
| Max DD | 26.34% |
| CAGR/Max DD | 1.44 |
EPS (Earnings per Share)
Revenue
Description: NMR Nomura Holdings February 13, 2026
Nomura Holdings Inc. (NYSE:NMR) is a global financial services firm headquartered in Tokyo that operates through three core segments: Wealth Management (providing investment advisory to high-net-worth individuals and families), Investment Management (running discretionary mandates, investment trusts, and institutional fund solutions), and Wholesale (executing sales and trading of debt, equity, FX and derivatives, and delivering investment-banking services such as underwriting, M&A advisory, and capital-raising).
In its most recent FY2025 results, Nomura reported net revenue of ¥1.13 trillion, a 4.2 % year-over-year increase driven largely by a 7 % rise in Wholesale trading volumes amid heightened market volatility and a 3 % boost in Wealth Management fees from rising client assets. The firm’s return on equity (ROE) held at 7.8 %, while the cost-to-income ratio improved to 64 % thanks to ongoing digitalization of back-office processes. Key macro drivers remain the prolonged low-interest-rate environment in Japan, which pressures net interest margins, and the strengthening yen, which compresses overseas earnings when translated back to yen.
For a deeper quantitative view of Nomura’s valuation dynamics and scenario-based risk metrics, you may find it useful to explore the analytics on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income: 360.17b TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.01 > 0.02 and ΔFCF/TA -0.62 > 1.0 |
| NWC/Revenue: 343.4% < 20% (prev -626.6%; Δ 969.9% < -1%) |
| CFO/TA 0.00 > 3% & CFO 264.20b > Net Income 360.17b |
| Net Debt (26015.65b) to EBITDA (529.89b): 49.10 < 3 |
| Current Ratio: 1.42 > 1.5 & < 3 |
| Outstanding Shares: last quarter (3.03b) vs 12m ago -1.11% < -2% |
| Gross Margin: 41.08% > 18% (prev 0.36%; Δ 4071 % > 0.5%) |
| Asset Turnover: 7.16% > 50% (prev 7.62%; Δ -0.46% > 0%) |
| Interest Coverage Ratio: 0.36 > 6 (EBITDA TTM 529.89b / Interest Expense TTM 2581.82b) |
Altman Z'' 1.86
| A: 0.24 (Total Current Assets 50553.49b - Total Current Liabilities 35508.27b) / Total Assets 61935.17b |
| B: 0.03 (Retained Earnings 2067.36b / Total Assets 61935.17b) |
| C: 0.02 (EBIT TTM 920.06b / Avg Total Assets 61232.51b) |
| D: 0.05 (Book Value of Equity 3128.60b / Total Liabilities 58120.58b) |
| Altman-Z'' Score: 1.86 = BBB |
Beneish M -1.65
| DSRI: 3.42 (Receivables 5077.72b/1563.41b, Revenue 4381.60b/4610.26b) |
| GMI: 0.88 (GM 41.08% / 36.16%) |
| AQI: 0.20 (AQ_t 0.18 / AQ_t-1 0.87) |
| SGI: 0.95 (Revenue 4381.60b / 4610.26b) |
| TATA: 0.00 (NI 360.17b - CFO 264.20b) / TA 61935.17b) |
| Beneish M-Score: -1.65 (Cap -4..+1) = CCC |
What is the price of NMR shares?
Over the past week, the price has changed by +7.65%, over one month by +1.31%, over three months by +26.22% and over the past year by +50.81%.
Is NMR a buy, sell or hold?
- StrongBuy: 0
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the NMR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 9.8 | 5% |
| Analysts Target Price | 9.8 | 5% |
| ValueRay Target Price | 12.5 | 34.6% |
NMR Fundamental Data Overview February 13, 2026
P/E Trailing = 12.3947
P/E Forward = 16.0772
P/S = 0.0135
P/B = 1.1817
P/EG = 0.851
Revenue TTM = 4381.60b JPY
EBIT TTM = 920.06b JPY
EBITDA TTM = 529.89b JPY
Long Term Debt = 15282.76b JPY (from longTermDebt, last quarter)
Short Term Debt = 16729.70b JPY (from shortTermDebt, last quarter)
Debt = 32012.47b JPY (from shortLongTermDebtTotal, last quarter)
Net Debt = 26015.65b JPY (from netDebt column, last quarter)
Enterprise Value = 31342.54b JPY (4235.95b + Debt 32012.47b - CCE 4905.87b)
Interest Coverage Ratio = 0.36 (Ebit TTM 920.06b / Interest Expense TTM 2581.82b)
EV/FCF = -36.08x (Enterprise Value 31342.54b / FCF TTM -868.58b)
FCF Yield = -2.77% (FCF TTM -868.58b / Enterprise Value 31342.54b)
FCF Margin = -19.82% (FCF TTM -868.58b / Revenue TTM 4381.60b)
Net Margin = 8.22% (Net Income TTM 360.17b / Revenue TTM 4381.60b)
Gross Margin = 41.08% ((Revenue TTM 4381.60b - Cost of Revenue TTM 2581.82b) / Revenue TTM)
Gross Margin QoQ = 42.40% (prev 42.03%)
Tobins Q-Ratio = 0.51 (Enterprise Value 31342.54b / Total Assets 61935.17b)
Interest Expense / Debt = 2.11% (Interest Expense 676.17b / Debt 32012.47b)
Taxrate = 30.08% (40.67b / 135.22b)
NOPAT = 643.30b (EBIT 920.06b * (1 - 30.08%))
Current Ratio = 1.42 (Total Current Assets 50553.49b / Total Current Liabilities 35508.27b)
Debt / Equity = 8.77 (Debt 32012.47b / totalStockholderEquity, last quarter 3651.82b)
Debt / EBITDA = 49.10 (Net Debt 26015.65b / EBITDA 529.89b)
Debt / FCF = -29.95 (negative FCF - burning cash) (Net Debt 26015.65b / FCF TTM -868.58b)
Total Stockholder Equity = 3521.00b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.59% (Net Income 360.17b / Total Assets 61935.17b)
RoE = 10.23% (Net Income TTM 360.17b / Total Stockholder Equity 3521.00b)
RoCE = 4.89% (EBIT 920.06b / Capital Employed (Equity 3521.00b + L.T.Debt 15282.76b))
RoIC = 3.34% (NOPAT 643.30b / Invested Capital 19289.10b)
WACC = 2.50% (E(4235.95b)/V(36248.41b) * Re(10.25%) + D(32012.47b)/V(36248.41b) * Rd(2.11%) * (1-Tc(0.30)))
Discount Rate = 10.25% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.69%
Fair Price DCF = unknown (Cash Flow -868.58b)
EPS Correlation: 50.11 | EPS CAGR: 27.68% | SUE: -0.01 | # QB: 0
Revenue Correlation: 77.80 | Revenue CAGR: 35.19% | SUE: 0.53 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.18 | Chg30d=-0.003 | Revisions Net=-1 | Analysts=1
EPS next Year (2027-03-31): EPS=0.78 | Chg30d=+0.028 | Revisions Net=+1 | Growth EPS=-5.7% | Growth Revenue=-1.3%